ReviewFrontiers in oncology2025
MicroRNAs in breast cancer-new frontiers in diagnosis, targeted therapy, and prognosis assessment.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- The Promise and Pursuit of MicroRNAs for Cancer Treatment.Biomolecules · 2026Review
- Regulation of epidermal growth factor receptors: The role of c-Cbl, Cdc42, and miRNAs in breast cancer.Biochemistry and biophysics reports · 2026Review
- Bioinformatics Analysis of microRNAs Associated with Metastatic Potential in Breast Cancer.Biology · 2026Article
- Review
- Advances and challenges in biomarker guided management of triple-negative breast cancer in the era of neoadjuvant chemo-immunotherapy.Frontiers in oncology · 2026Review
- Unravelling the nexus of non-coding RNAs in cancer stemness and therapeutic drug resistance.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is one of the most common malignancies among women globally, with an annually increasing incidence rate. Its complex pathogenesis and high heterogeneity pose significant challenges to clinical diagnosis and treatment. Traditional diagnostic methods and therapeutic approaches have limitations in improving patient survival rates and prognosis, thus urgently necessitating the identification of novel biomarkers and therapeutic targets. MicroRNA (miRNA), a class of endogenous non-coding small RNA molecules with a length of approximately 20-24 nucleotides, finely regulates gene expression by binding to the 3' untranslated region of target mRNAs, inhibiting gene translation, or promoting mRNA degradation. In 2024, the Nobel Prize in Physiology or Medicine was awarded for research related to miRNA. Numerous studies have demonstrated that miRNAs play pivotal roles in the initiation, progression, invasion, metastasis, and drug resistance of breast cancer. Aberrant expression of specific miRNAs is closely associated with the molecular subtypes, prognosis, and treatment response of breast cancer, suggesting their potential as diagnostic and prognostic biomarkers. To explore the potential value of miRNA in the diagnosis and treatment of breast cancer, this article systematically reviews the latest research progress on the role of miRNAs in the diagnosis and treatment of breast cancer, with a focus on their application as tumor markers in early diagnosis, molecular subtyping, and therapeutic response monitoring. It elucidates the possibilities of miRNAs as therapeutic targets and tools in targeted therapy, including the current research status of miRNA mimics and inhibitors in breast cancer treatment. Furthermore, it analyzes the role of miRNAs in prognosis assessment, exploring their correlation with patient survival rates, recurrence risks, and treatment responsiveness. Additionally, this article discusses the challenges faced by miRNA research in precision medicine for breast cancer and future directions, providing new insights and strategies for early diagnosis, individualized treatment, and prognosis assessment of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.